Carisma Therapeutics, Inc. (CARM)
OTCMKTS
· Delayed Price · Currency is USD
0.0415
-0.0006 (-1.52%)
At close: Mar 6, 2026
Carisma Therapeutics Revenue
Carisma Therapeutics had revenue of $45.25M in the quarter ending September 30, 2025, with 1,236.78% growth. This brings the company's revenue in the last twelve months to $52.63M, up 159.68% year-over-year. In the year 2024, Carisma Therapeutics had annual revenue of $19.63M with 31.59% growth.
Revenue (ttm)
52.63M
Revenue Growth
+159.68%
P/S Ratio
0.03
Revenue / Employee
1.14M
Employees
46
Market Cap
1.83M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 19.63M | 4.71M | 31.59% |
| Dec 31, 2023 | 14.92M | 5.09M | 51.71% |
| Dec 31, 2022 | 9.83M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCarisma Therapeutics News
- 3 months ago - Carisma Announces Delisting from Nasdaq and SEC Deregistration - PRNewsWire
- 1 year ago - Carisma Therapeutics Provides Corporate Updates - PRNewsWire
- 1 year ago - Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference - PRNewsWire
- 1 year ago - Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference - PRNewsWire
- 1 year ago - Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize Pipeline - PRNewsWire
- 1 year ago - Carisma Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference - PRNewsWire
- 1 year ago - Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting® 2024 - PRNewsWire
- 1 year ago - Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma - PRNewsWire